Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Alimentary Pharmacology & Therapeutics|June 23, 2022
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risksGeorge V Papatheodoridis, Kostas Mimidis, Spilios Manolakopoulos, et al.
European Journal of Gastroenterology & Hepatology|May 25, 2021
Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in GreeceAnthia Gatopoulou, Dimitrios K Christodoulou, Konstantinos H Katsanos, et al.
Journal of Hepatology|July 6, 2026
Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohortGeorge V Papatheodoridis, George Dalekos, Ramazan Idilman, et al.
European Journal of Gastroenterology & Hepatology|November 10, 2010
Pegylated interferon alfa-2b pen device and ribavirin treatment for patients with chronic hepatitis C: an evaluation of patient satisfactionParaskevi Aggelopoulou-Tiga, Dimitrios Dimitroulopoulos, Konstantinos Kaligeros, et al.
Journal of Hepatology|December 19, 2015
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyGeorge Papatheodoridis, George Dalekos, Vana Sypsa, et al.
Journal of Hepatology|June 20, 2020
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
JHEP Reports : Innovation in Hepatology|May 27, 2021
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
The International Journal on Drug Policy|February 23, 2024
High levels of all-cause mortality among people who inject drugs from 2018 to 2022Sotirios Roussos, Theodoros Angelopoulos, Evangelos Cholongitas, et al.
Journal of Viral Hepatitis|May 14, 2024
Incidence of primary hepatitis C infection among people who inject drugs during 2012-2020 in Athens, GreeceSotirios Roussos, Christos Bagos, Theodoros Angelopoulos, et al.
Hepatology (Baltimore, Md.)|June 17, 2017
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis BGeorge V Papatheodoridis, Ramazan Idilman, George N Dalekos, et al.
Pageof 11